35 related articles for article (PubMed ID: 38630010)
1. Defining the Genomic Landscape of Diffuse Sclerosing Papillary Thyroid Carcinoma: Prognostic Implications of RET Fusions.
Scholfield DW; Fitzgerald CWR; Boe LA; Eagan A; Levyn H; Xu B; Tuttle RM; Fagin JA; Shaha AR; Shah JP; Wong RJ; Patel SG; Ghossein R; Ganly I
Ann Surg Oncol; 2024 Jun; ():. PubMed ID: 38847983
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
4. Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan.
Yamazaki H; Kunisaki C; Sugimori M; Rino Y; Saito A
Endocrine; 2024 Feb; ():. PubMed ID: 38407696
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
7. Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
Toda S; Hiroshima Y; Iwasaki H; Masudo K
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38630010
[TBL] [Abstract][Full Text] [Related]
8. High-Grade Non-Anaplastic Thyroid Carcinomas of Follicular Cell Origin: A Review of Poorly Differentiated and High-Grade Differentiated Carcinomas.
Cracolici V; Cipriani NA
Endocr Pathol; 2023 Mar; 34(1):34-47. PubMed ID: 36692728
[TBL] [Abstract][Full Text] [Related]
9. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
Xu B; Ghossein R
Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
[TBL] [Abstract][Full Text] [Related]
10. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
Nikiforov YE
Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
Volante M; Lam AK; Papotti M; Tallini G
Endocr Pathol; 2021 Mar; 32(1):63-76. PubMed ID: 33543394
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
